Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
13 Dec 2023
13 Dec 2023
Historique:
received:
11
06
2023
accepted:
29
11
2023
revised:
23
10
2023
medline:
14
12
2023
pubmed:
14
12
2023
entrez:
13
12
2023
Statut:
aheadofprint
Résumé
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p = 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p = 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p = 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p = 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.
Identifiants
pubmed: 38092959
doi: 10.1038/s41409-023-02167-1
pii: 10.1038/s41409-023-02167-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109:3658–66. https://doi.org/10.1182/blood-2006-06-025627 .
doi: 10.1182/blood-2006-06-025627
pubmed: 17213292
Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301:2349–61.
doi: 10.1001/jama.2009.813
pubmed: 19509382
pmcid: 3163846
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74. https://doi.org/10.1182/blood-2009-07-235358 .
doi: 10.1182/blood-2009-07-235358
pubmed: 19880497
Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52. https://doi.org/10.1056/NEJMra1406184 .
doi: 10.1056/NEJMra1406184
pubmed: 26376137
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65. https://doi.org/10.1182/blood-2009-11-254441 .
doi: 10.1182/blood-2009-11-254441
pubmed: 20385793
Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127:29–41. https://doi.org/10.1182/blood-2015-07-604496 .
doi: 10.1182/blood-2015-07-604496
pubmed: 26660431
pmcid: 4705608
Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer. 2005;43:227–38. https://doi.org/10.1002/gcc.20193 .
doi: 10.1002/gcc.20193
pubmed: 15846790
Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26:2462–8. https://doi.org/10.1038/leu.2012.135 .
doi: 10.1038/leu.2012.135
pubmed: 22699419
Schlenk RF, Dohner K, Mack S, Stoppel M, Kiraly F, Gotze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acutemyeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010;28:4642–8. https://doi.org/10.1200/JCO.2010.28.6856 .
doi: 10.1200/JCO.2010.28.6856
pubmed: 20805454
Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, et al. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. Haematologica. 2011;96:972–9. https://doi.org/10.3324/haematol.2011.041004 .
doi: 10.3324/haematol.2011.041004
pubmed: 21459795
pmcid: 3128215
Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2:e427–436. https://doi.org/10.1016/S2352-3026(15)00148-9 .
doi: 10.1016/S2352-3026(15)00148-9
pubmed: 26686044
Bowen D, Groves MJ, Burnett AK, Patel Y, Allen C, Green C, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23:203–6. https://doi.org/10.1038/leu.2008.173 .
doi: 10.1038/leu.2008.173
pubmed: 18596741
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The medical research council adult and children’s leukaemia working parties. Blood. 1998;92:2322–33.
doi: 10.1182/blood.V92.7.2322
pubmed: 9746770
Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791–7. https://doi.org/10.1200/JCO.2008.16.0259 .
doi: 10.1200/JCO.2008.16.0259
pubmed: 18695255
Haferlach C, Alpermann T, Schnittger S, Kern W, Chromik J, Schmid C, et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood. 2012;119:2122–5. https://doi.org/10.1182/blood-2011-10-385781 .
doi: 10.1182/blood-2011-10-385781
pubmed: 22207733
Poire X, Labopin M, Cornelissen JJ, Volin L, Richard Espiga C, Veelken JH, et al. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: a study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT). Am J Hematol. 2015;90:719–24. https://doi.org/10.1002/ajh.24069 .
doi: 10.1002/ajh.24069
pubmed: 26010466
Poire X, Labopin M, Polge E, Forcade E, Ganser A, Volin L, et al. Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020;105:414–23. https://doi.org/10.3324/haematol.2019.216168 .
doi: 10.3324/haematol.2019.216168
pubmed: 31048355
pmcid: 7012466
Poire X, Labopin M, Polge E, Volin L, Finke J, Ganser A, et al. The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. Am J Hematol. 2020;95:282–94. https://doi.org/10.1002/ajh.25714 .
doi: 10.1002/ajh.25714
pubmed: 31876307
Chilton L, Hills RK, Harrison CJ, Burnett AK, Grimwade D, Moorman AV. Hyperdiploidy with 49–65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. Leukemia. 2014;28:321–8. https://doi.org/10.1038/leu.2013.198 .
doi: 10.1038/leu.2013.198
pubmed: 23812419
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004 .
doi: 10.1016/j.bbmt.2009.07.004
pubmed: 19896087
pmcid: 2861656
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610–1. https://doi.org/10.1038/bmt.2015.305 .
doi: 10.1038/bmt.2015.305
Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. https://doi.org/10.1182/blood.2022016867 .
doi: 10.1182/blood.2022016867
pubmed: 35797463
Luquet I, Lai JL, Barin C, Baranger L, Bilhou-Nabera C, Lippert E, et al. Hyperdiploid karyotypes in acute myeloid leukemia define a novel entity: a study of 38 patients from the Groupe Francophone de Cytogenetique Hematologique (GFCH). Leukemia. 2008;22:132–7. https://doi.org/10.1038/sj.leu.2404974 .
doi: 10.1038/sj.leu.2404974
pubmed: 17928884
Lazarevic V, Rosso A, Juliusson G, Antunovic P, Rangert-Derolf A, Lehmann S, et al. Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia. Am J Hematol. 2015;90:800–5. https://doi.org/10.1002/ajh.24091 .
doi: 10.1002/ajh.24091
pubmed: 26088289
Lazarevic VL, Rosso A, Juliusson G, Antunovic P, Derolf AR, Deneberg S, et al. Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: a population-based study from the Swedish AML registry. Eur J Haematol. 2017;98:493–500. https://doi.org/10.1111/ejh.12861 .
doi: 10.1111/ejh.12861
pubmed: 28152233
Farag SS, Archer KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, et al. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002;21:1041–51.
pubmed: 12370753
Wolman SR, Gundacker H, Appelbaum FR, Slovak ML.Southwest Oncology G. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2002;100:29–35. https://doi.org/10.1182/blood.v100.1.29 . e-pub ahead of print 2002/06/19.
doi: 10.1182/blood.v100.1.29
pubmed: 12070004
Schoch C, Haase D, Fonatsch C, Haferlach T, Loffler H, Schlegelberger B, et al. The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group. Br J Haematol. 1997;99:605–11. https://doi.org/10.1046/j.1365-2141.1997.4473257.x .
doi: 10.1046/j.1365-2141.1997.4473257.x
pubmed: 9401073
Paulsson K, Johansson B. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathol Biol. 2007;55:37–48. https://doi.org/10.1016/j.patbio.2006.04.007 .
doi: 10.1016/j.patbio.2006.04.007
pubmed: 16697122
Schoch C, Kohlmann A, Dugas M, Kern W, Schnittger S, Haferlach T. Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups. Genes Chromosomes Cancer. 2006;45:1164–8. https://doi.org/10.1002/gcc.20380 .
doi: 10.1002/gcc.20380
pubmed: 17001623
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. https://doi.org/10.1182/blood.2022015850 .
doi: 10.1182/blood.2022015850
pubmed: 35767897
pmcid: 9479031
Alpermann T, Haferlach C, Eder C, Nadarajah N, Meggendorfer M, Kern W, et al. AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients. Leuk Res. 2015;39:265–72. https://doi.org/10.1016/j.leukres.2014.11.026 .
doi: 10.1016/j.leukres.2014.11.026
pubmed: 25592059
Bhatnagar B, Eisfeld AK, Kohlschmidt J, Mrozek K, Nicolet D, Papaioannou D, et al. Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. Leukemia. 2020;34:358–68. https://doi.org/10.1038/s41375-019-0560-3 .
doi: 10.1038/s41375-019-0560-3
pubmed: 31462731
Liu J, Han W, Cai X, Wang Z, Cao L, Hua H, et al. Molecular genetic and clinical characterization of acute myeloid leukemia with trisomy 8 as the sole chromosome abnormality. Hematology. 2022;27:565–74. https://doi.org/10.1080/16078454.2022.2071799 .
doi: 10.1080/16078454.2022.2071799
pubmed: 35549661
Zong X, Yao H, Wen L, Ma L, Wang Q, Yang Z, et al. ASXL1 mutations are frequent in de novo AML with trisomy 8 and confer an unfavorable prognosis. Leuk Lymphoma. 2017;58:204–6. https://doi.org/10.1080/10428194.2016.1179296 .
doi: 10.1080/10428194.2016.1179296
pubmed: 27736271
Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood. 2007;110:1308–16. https://doi.org/10.1182/blood-2007-02-072595 .
doi: 10.1182/blood-2007-02-072595
pubmed: 17485549
Herold T, Metzeler KH, Vosberg S, Hartmann L, Rollig C, Stolzel F, et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124:1304–11. https://doi.org/10.1182/blood-2013-12-540716 .
doi: 10.1182/blood-2013-12-540716
pubmed: 24923295
Silva FP, Lind A, Brouwer-Mandema G, Valk PJ, Giphart-Gassler M. Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica. 2007;92:1123–6. https://doi.org/10.3324/haematol.11296 .
doi: 10.3324/haematol.11296
pubmed: 17650443
Kuwatsuka Y, Miyamura K, Suzuki R, Kasai M, Maruta A, Ogawa H, et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood. 2009;113:2096–103. https://doi.org/10.1182/blood-2008-03-145862 .
doi: 10.1182/blood-2008-03-145862
pubmed: 19126873
Poire X, Labopin M, Polge E, Blaise D, Chevallier P, Maertens J, et al. Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. Am J Hematol. 2019;94:231–9. https://doi.org/10.1002/ajh.25355 .
doi: 10.1002/ajh.25355
pubmed: 30456896
Potdar R, Varadi G, Fein J, Labopin M, Nagler A, Shouval R. Prognostic scoring systems in allogeneic hematopoietic stem cell transplantation: where do we stand? Biol Blood Marrow Transpl. 2017;23:1839–46. https://doi.org/10.1016/j.bbmt.2017.07.028 .
doi: 10.1016/j.bbmt.2017.07.028
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. https://doi.org/10.1182/blood-2005-05-2004 .
doi: 10.1182/blood-2005-05-2004
pubmed: 15994282
pmcid: 1895304
Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249–56.
doi: 10.1200/JCO.2013.53.8157
pubmed: 25154831
pmcid: 4178523